Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Breast Neoplasms 12Neoplasms 8Multiple Myeloma 8Melanoma 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Hematologic Neoplasms 6Urinary Bladder Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Thyroid Neoplasms 4Sarcoma 4Ovarian Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Endometrial Neoplasms 4Adenocarcinoma 4Urothelial Cancer 3Thyroid Cancer, Papillary 3Stomach Neoplasms 3Salivary Gland Neoplasms 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Neurofibroma, Plexiform 3Neuroendocrine Tumors 3

Interventions

nilotinib 1bosutinib 1asciminib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × 90 days × Clear all
NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡